<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089230</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0116</org_study_id>
    <secondary_id>NCI-2014-01518</secondary_id>
    <nct_id>NCT02089230</nct_id>
  </id_info>
  <brief_title>MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy</brief_title>
  <official_title>Phase I/II Trial of MEK Inhibitor MEK162 in Patients With Relapsed and or Refractory Acute Myeloid Leukemia and Patients With Poor Prognosis Acute Myeloid Leukemia Not Suitable for or Unwilling to Receive Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of&#xD;
      MEK162 that can be given to patients with advanced leukemia.&#xD;
&#xD;
      This is an investigational study. MEK162 is not FDA approved or commercially available. It is&#xD;
      currently being used for research purposes only. The study doctor can explain how the study&#xD;
      drug is designed to work.&#xD;
&#xD;
      Up to 57 patients total will take part in both phases of this study . All will be enrolled at&#xD;
      MD Anderson.&#xD;
&#xD;
      The goal of Phase 2 of this clinical research study is to learn if MEK162 can help to control&#xD;
      AML in older patients with advanced leukemia. The safety of this drug will also be studied.&#xD;
&#xD;
      This is an investigational study. MEK162 is not FDA approved or commercially available. It is&#xD;
      currently being used for research purposes only. The study doctor can explain how the study&#xD;
      drug is designed to work.&#xD;
&#xD;
      Up to 57 patients total will take part in both phases of this study. All will be enrolled at&#xD;
      MD Anderson.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I:&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be assigned to a study&#xD;
      group based on when you join this study. Up to 2 groups of 3-6 participants will be enrolled&#xD;
      in Phase 1 of the study.&#xD;
&#xD;
      If you are enrolled in Phase 1, the dose of MEK162 you receive will depend on when you joined&#xD;
      this study. The first group of participants will receive the lowest dose level of MEK162. The&#xD;
      second group will receive a higher dose of MEK162 than the group before it, if no intolerable&#xD;
      side effects were seen. This is designed to find the highest tolerable dose of MEK 162.&#xD;
&#xD;
      Participants in Phase 2 will then receive the highest tolerated dose that was found in Phase&#xD;
      1.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      You will take MEK162 tablets by mouth 2 times a day (about 12 hours apart) every day with a&#xD;
      full cup of water.&#xD;
&#xD;
      There are 4 weeks in each study cycle.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      On Day 1 of Cycle 1:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 4 teaspoons) will be drawn for routine tests and blood sugar testing.&#xD;
&#xD;
      On Days 4 and 8 of Cycle 1, blood (about 4 teaspoons) will be drawn for routine tests and&#xD;
      blood sugar testing.&#xD;
&#xD;
      Sometime during Days 13-27 of each cycle and again on Day 28 of Cycles 2 and beyond, the&#xD;
      study staff will call you and ask about any drugs you may be taking and any side effects you&#xD;
      may be having. The calls should last less than 10 minutes each time.&#xD;
&#xD;
      On Day 28 of Cycle 1, you will have a bone marrow aspirate and/or biopsy to check the status&#xD;
      of the disease and for biomarker and cytogenetic testing. If bone marrow cannot be collected,&#xD;
      blood (about 1-2 teaspoons) will be drawn for these tests.&#xD;
&#xD;
      You will have an EKG and either an ECHO or MUGA scan to check your heart function.&#xD;
&#xD;
      On Day 1 of Cycle 2 and beyond:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 4 teaspoons) will be drawn for routine tests and blood sugar testing.&#xD;
&#xD;
        -  Urine will be collected for routine tests.&#xD;
&#xD;
        -  You will have an eye exam by an eye doctor.&#xD;
&#xD;
        -  If you can become pregnant, blood (about 1 teaspoon) or urine will be collected for a&#xD;
           pregnancy test.&#xD;
&#xD;
      On visits when you have blood sugar testing, you should fast for at least 8 hours before the&#xD;
      blood draw.&#xD;
&#xD;
      On visits when you have urine collected, you will be given containers to collect your urine&#xD;
      over 24 hours if the doctor thinks it is needed.&#xD;
&#xD;
      If it is more convenient to you, you may be able to have some of your blood draws done away&#xD;
      from MD Anderson. The study staff will discuss this with you.&#xD;
&#xD;
      Every two or three months during your treatment, you will have an echocardiogram (ECHO) or a&#xD;
      multigated acquisition (MUGA) scan to check your heart function.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You may continue taking the study drug for as long as the doctor thinks it is in your best&#xD;
      interest. You will no longer be able to take the study drug if the disease gets worse, if&#xD;
      intolerable side effects occur, or if you are unable to follow study directions.&#xD;
&#xD;
      Your participation on the study will be over once you have completed the end-of-treatment&#xD;
      visit.&#xD;
&#xD;
      End-of-Treatment Visit:&#xD;
&#xD;
      After your last dose of study drug:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2 teaspoons) will be drawn for routine tests&#xD;
&#xD;
        -  If the doctor thinks it is needed, you will have a bone marrow aspirate and/or biopsy to&#xD;
           check the status of the disease and for biomarker, PD, and/or cytogenetic testing. If&#xD;
           you have already had a bone marrow aspirate and/or biopsy recently and your doctor&#xD;
           thinks repeating it is not needed, leftover bone marrow will be used for these tests. If&#xD;
           bone marrow cannot be collected, blood (about 1-2 teaspoons) will be drawn for these&#xD;
           tests.&#xD;
&#xD;
        -  You will have an EKG.&#xD;
&#xD;
      Phase II:&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be assigned to a study&#xD;
      group based on when you join this study. Up to 42 participants will be enrolled in Phase 2 of&#xD;
      the study.&#xD;
&#xD;
      Participants in Phase 1 were given a dose of MEK162 based on when they joined the study.&#xD;
      Groups of participants were given different dose levels until the highest tolerable dose of&#xD;
      MEK162 was found.&#xD;
&#xD;
      If you are enrolled in Phase 2, you will receive MEK162 at the highest dose that was&#xD;
      tolerated in Phase 1.&#xD;
&#xD;
      Study Drug Administration:&#xD;
&#xD;
      You will take MEK162 tablets by mouth 2 times a day (about 12 hours apart) every day with a&#xD;
      full cup of water.&#xD;
&#xD;
      There are 4 weeks in each study cycle.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      On Day 1 of Cycle 1:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 4 teaspoons) will be drawn for routine tests and blood sugar testing.&#xD;
&#xD;
      On Days 4 and 8 of Cycle 1, blood (about 4 teaspoons) will be drawn for routine tests and&#xD;
      blood sugar testing.&#xD;
&#xD;
      Sometime during Days 13-27 of each cycle and again on Day 28 of Cycles 2 and beyond, the&#xD;
      study staff will call you and ask about any drugs you may be taking and any side effects you&#xD;
      may be having. The calls should last less than 10 minutes each time.&#xD;
&#xD;
      On Day 28 of Cycle 1, you will have a bone marrow aspirate and/or biopsy to check the status&#xD;
      of the disease and for biomarker and cytogenetic testing. If bone marrow cannot be collected,&#xD;
      blood (about 1-2 teaspoons) will be drawn for these tests.&#xD;
&#xD;
      You will have an EKG and either an ECHO or MUGA scan to check your heart function.&#xD;
&#xD;
      On Day 1 of Cycle 2 and beyond:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 4 teaspoons) will be drawn for routine tests and blood sugar testing.&#xD;
&#xD;
        -  Urine will be collected for routine tests.&#xD;
&#xD;
        -  You will have an eye exam by an eye doctor.&#xD;
&#xD;
        -  If you can become pregnant, blood (about 1 teaspoon) or urine will be collected for a&#xD;
           pregnancy test.&#xD;
&#xD;
      On visits when you have blood sugar testing, you should fast for at least 8 hours before the&#xD;
      blood draw.&#xD;
&#xD;
      On visits when you have urine collected, you will be given containers to collect your urine&#xD;
      over 24 hours if the doctor thinks it is needed.&#xD;
&#xD;
      If it is more convenient to you, you may be able to have some of your blood draws done away&#xD;
      from MD Anderson. The study staff will discuss this with you.&#xD;
&#xD;
      Every two or three months during your treatment, you will have an echocardiogram (ECHO) or a&#xD;
      multigated acquisition (MUGA) scan to check your heart function.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You may continue taking the study drug for as long as the doctor thinks it is in your best&#xD;
      interest. You will no longer be able to take the study drug if the disease gets worse, if&#xD;
      intolerable side effects occur, or if you are unable to follow study directions.&#xD;
&#xD;
      Your participation on the study will be over once you have completed the end-of-treatment&#xD;
      visit.&#xD;
&#xD;
      End-of-Treatment Visit:&#xD;
&#xD;
      After your last dose of study drug:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2 teaspoons) will be drawn for routine tests&#xD;
&#xD;
        -  If the doctor thinks it is needed, you will have a bone marrow aspirate and/or biopsy to&#xD;
           check the status of the disease and for biomarker, PD, and/or cytogenetic testing. If&#xD;
           you have already had a bone marrow aspirate and/or biopsy recently and your doctor&#xD;
           thinks repeating it is not needed, leftover bone marrow will be used for these tests. If&#xD;
           bone marrow cannot be collected, blood (about 1-2 teaspoons) will be drawn for these&#xD;
           tests.&#xD;
&#xD;
        -  You will have an EKG.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was terminated due to slow accrual&#xD;
  </why_stopped>
  <start_date type="Actual">August 27, 2014</start_date>
  <completion_date type="Actual">June 5, 2019</completion_date>
  <primary_completion_date type="Actual">June 5, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of MEK 162 in Participants With Advanced Leukemias</measure>
    <time_frame>28 days</time_frame>
    <description>Maximum tolerated dose is the highest dose level in which &lt;2 patients of 6 develop dose limiting toxicity (DLT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Response</measure>
    <time_frame>Assessed after one 28-day cycle of treatment</time_frame>
    <description>Response is Complete Remission (CR) or CR with incomplete blood count recovery (CRi) according to International Working Group (IWG) consensus criteria for treatment response in Acute Myeloid Leukemia (AML) (modified): Morphological Complete Remission (CR): Normalization of the peripheral blood absolute neutrophil count &gt; 1.0x109/L, platelets &gt; than 100x109/L no residual evidence of extramedullary disease and bone marrow aspirate with ≤ 5% blasts, no blasts with Auer rods (AML only); and Morphological Complete Remission with incomplete blood count recovery (CRi): Same as CR but without normalization of the peripheral blood absolute neutrophil and platelet count.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Phase I Cohort 1 - MEK 162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I Starting Dose of MEK 162: 30 mg by mouth twice a day in a 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Cohort 2 - MEK 162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II Cohort 3 - MDK 162</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEK 162</intervention_name>
    <description>Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.&#xD;
Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I.</description>
    <arm_group_label>Phase I Cohort 1 - MEK 162</arm_group_label>
    <arm_group_label>Phase I Cohort 2 - MEK 162</arm_group_label>
    <arm_group_label>Phase II Cohort 3 - MDK 162</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. PHASE I -- a. Primary or secondary AML according to World Health Organization (WHO)&#xD;
             classification, with relapsed or refractory disease or newly diagnosed older subjects&#xD;
             (greater than or equal to 65 years of age), not candidates for intensive chemotherapy;&#xD;
             b. Subjects with MDS, International Prognostic Scoring System (IPSS) Int-2 or high&#xD;
             risk (RAEB-2 only, i.e. greater than or equal to 10% blast) who are resistant or&#xD;
             intolerant to standard treatment and are not candidates for transplantation; c.&#xD;
             Subjects with ALL, relapsed, refractory or intolerant to standard treatment and for&#xD;
             whom no effective treatment options are available.&#xD;
&#xD;
          2. Age greater or equal to 18 years.&#xD;
&#xD;
          3. Patients should be willing and able to give informed consent.&#xD;
&#xD;
          4. Eastern Cooperative Group (ECOG) PS less than or equal to 2.&#xD;
&#xD;
          5. PHASE II -- Patients aged 60 and older with newly diagnosed primary or secondary AML&#xD;
             according to WHO classification, without any prior therapy for AML with the exception&#xD;
             of (a) emergency Leukapheresis and (b) emergency treatment for hyperleukocytosis with&#xD;
             hydroxyurea that is allowed until 24 hours before start of the trial treatment. Note:&#xD;
             Prior therapy for preexisting hematological condition e.g. MDS or Myeloproliferative&#xD;
             Disorder (MPD), including but not limited to hypomethylating agents is allowed until&#xD;
             at least 2 weeks have elapsed from completion of that agent before the first dose of&#xD;
             MEK 162.&#xD;
&#xD;
          6. Patients must meet at least one of the following conditions: a. Age greater than or&#xD;
             equal to 75 years; b. Age greater or equal to 60 and less than 75 years with at least&#xD;
             one of the following poor prognostic factors: i. Secondary AML, as determined by known&#xD;
             and documented exposure to chemotherapy or radiation therapy; ii. antecedent history&#xD;
             of MDS or myeloproliferative disorder according to WHO criteria for at least 3 months&#xD;
             prior to trial entry; iii. unfavorable cytogenetic abnormalities including chromosome&#xD;
             5 and 7 as well as complex; iv. ECOG Performance status 2. (Phase II ONLY)&#xD;
&#xD;
          7. Patients are willing and able to give informed consent. (Phase II only)&#xD;
&#xD;
          8. Only patients with mutated RAS (KRAS and NRAS) mutations are eligible to participate.&#xD;
             (Phase II only)&#xD;
&#xD;
          9. Adequate cardiac function defined as: --left ventricular ejection fraction (LVEF)&#xD;
             greater than or equal to 50% as determined by a multigated acquisition (MUGA) scan or&#xD;
             echocardiogram; -- QTcF interval less than or equal to 480 ms. (Phase II only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. PHASE I and II -- Administration of any antineoplastic therapy within at least 4 weeks&#xD;
             (cytotoxic chemotherapy) or 2 weeks (biological and targeted therapy; hypomethylating&#xD;
             agents are considered to be biological therapy) of that therapy of the first MEK&#xD;
             162/MEK 162 dose; except the use of hydroxyurea which can be administered up to 5&#xD;
             g/day up to 24 hours before the initiation of the study drug.&#xD;
&#xD;
          2. Patients should not have received an investigational agent for at least 2 weeks prior&#xD;
             to the first study drug dose.&#xD;
&#xD;
          3. Clinical evidence of active Central Nervous System (CNS) leukemia requiring active&#xD;
             therapy; prior CNS leukemia well-controlled by ongoing therapy is allowed.&#xD;
&#xD;
          4. Active and uncontrolled infection including but not limited to known infection with&#xD;
             HIV, active hepatitis B, or hepatitis C.&#xD;
&#xD;
          5. Major surgery within two weeks prior to trial entry.&#xD;
&#xD;
          6. Liver function tests above the following limits at the screening: total bilirubin &gt;&#xD;
             1.5 x Upper Limit of Normal (ULN) unless related to Gilbert's syndrome or hemolysis,&#xD;
             AST and/or ALT &gt; 2.5 X ULN, or for subjects with liver involvement Aspartate&#xD;
             Aminotransferase (AST) and/or Alanine transaminase (ALT) &gt; 5 x ULN.&#xD;
&#xD;
          7. Serum creatinine &gt; 1.5 x ULN and/or Creatinine Clearance (CrCl) &lt; 30 mL/min at&#xD;
             screening (calculation according to Cockcroft &amp; Gault formula).&#xD;
&#xD;
          8. Pregnant or nursing (lactating) women;&#xD;
&#xD;
          9. Female patients of childbearing potential and male patients with partners of&#xD;
             childbearing potential who are not willing ot use highly effective methods of&#xD;
             contraception throughout the study and for 1 month after study drug discontinuation.&#xD;
             Highly effective contraception methods include: **Total abstinence; or **Male or&#xD;
             female sterilization; **Combination of any two of the following (a+b or a+c or b+c);&#xD;
             a. Use of oral, injected, or implanted hormonal methods of contraception; b. Placement&#xD;
             of an intrauterine device (IUD) or intrauterine system (IUS); c. Barrier methods of&#xD;
             contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with&#xD;
             spermicidal foam/gel/film/cream/vaginal suppository.&#xD;
&#xD;
         10. Female patients with reproductive potential who do not have a negative blood or urine&#xD;
             pregnancy test at screening;&#xD;
&#xD;
         11. History of significant difficulty swallowing, malabsorption or other chronic&#xD;
             gastro-intestinal disease or conditions that may hamper compliance and/or absorption&#xD;
             of the tested product.&#xD;
&#xD;
         12. Has significant cardiac conduction abnormalities and/ or pacemaker or any of the&#xD;
             following criteria: -- History of acute coronary syndromes (including myocardial&#xD;
             infarction, unstable angina, Coronary Artery Bypass Grafting (CABG), coronary&#xD;
             angioplasty, or stenting) &lt;6 months prior to screening, --Symptomatic chronic heart&#xD;
             failure; evidence of clinically significant cardiac arrhythmias and/or conduction&#xD;
             abnormalities &lt; 6 months prior to screening --Uncontrolled arterial hypertension,&#xD;
             defined as BP &gt; 140/100 mmHg (average of 3 consecutive readings)&#xD;
&#xD;
         13. History or current evidence of central serous retinopathy (CSR), retinal vein&#xD;
             occlusion (RVO).&#xD;
&#xD;
         14. Any ophthalmopathy visible at screening that would be considered a risk factor for CSR&#xD;
             or RVO by the ophthalmologist (e.g. uncontrolled glaucoma or ocular hypertension,&#xD;
             uncontrolled diabetes mellitus, history of hyperviscosity or hypercoagulability&#xD;
             syndromes).&#xD;
&#xD;
         15. Subjects with active other tumors, except early stage squamous cell carcinoma of the&#xD;
             skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia (CIN).&#xD;
&#xD;
         16. Patients who have neuromuscular disorders that are associated with elevated Creatinine&#xD;
             Kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral&#xD;
             sclerosis, spinal muscular atrophy).&#xD;
&#xD;
         17. Patients who are planning on embarking on a new strenuous exercise regimen after first&#xD;
             dose of study treatment. NB: Muscular activities, such as strenuous exercise, that can&#xD;
             result in significant increases in plasma CK levels should be avoided while on MEK162&#xD;
             treatment.&#xD;
&#xD;
         18. Impairment of gastrointestinal function or gastrointestinal disease (e.g., ulcerative&#xD;
             disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel&#xD;
             resection).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Ravandi-Kashani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 13, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <results_first_submitted>October 30, 2020</results_first_submitted>
  <results_first_submitted_qc>March 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2021</results_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Advanced leukemias</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>MEK 162</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02089230/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 9/2014 to 9/2017</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase I Cohort 1 - MEK 162</title>
          <description>Phase I Starting Dose of MEK 162: 30 mg by mouth twice a day in a 28 day cycle.</description>
        </group>
        <group group_id="P2">
          <title>Phase I Cohort 2 - MEK 162</title>
          <description>Phase I Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.</description>
        </group>
        <group group_id="P3">
          <title>Phase II Cohort 3 - MDK 162</title>
          <description>Phase II Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Seeking Alternative Therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I Cohort 1 - MEK 162</title>
          <description>Phase I Starting Dose of MEK 162: 30 mg by mouth twice a day in a 28 day cycle.</description>
        </group>
        <group group_id="B2">
          <title>Phase I Cohort 2 - MEK 162</title>
          <description>Phase I Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.</description>
        </group>
        <group group_id="B3">
          <title>Phase II Cohort 3 - MDK 162</title>
          <description>Phase II Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="33" upper_limit="74"/>
                    <measurement group_id="B2" value="63" lower_limit="31" upper_limit="77"/>
                    <measurement group_id="B3" value="64.5" lower_limit="33" upper_limit="85"/>
                    <measurement group_id="B4" value="64" lower_limit="31" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of MEK 162 in Participants With Advanced Leukemias</title>
        <description>Maximum tolerated dose is the highest dose level in which &lt;2 patients of 6 develop dose limiting toxicity (DLT).</description>
        <time_frame>28 days</time_frame>
        <population>Maximum Tolerated Dose (MTD) was not done for the Phase II portion of the study, therefore 0 participants in the Phase II portion of the study were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Cohort 1 - MEK 162</title>
            <description>Phase I Starting Dose of MEK 162: 30 mg by mouth twice a day in a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Phase I Cohort 2 - MEK 162</title>
            <description>Phase I Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.</description>
          </group>
          <group group_id="O3">
            <title>Phase II Cohort 3 - MDK 162</title>
            <description>Phase II Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of MEK 162 in Participants With Advanced Leukemias</title>
          <description>Maximum tolerated dose is the highest dose level in which &lt;2 patients of 6 develop dose limiting toxicity (DLT).</description>
          <population>Maximum Tolerated Dose (MTD) was not done for the Phase II portion of the study, therefore 0 participants in the Phase II portion of the study were analyzed.</population>
          <units>Milligrams (mg)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The MTD was not determined until cohort 2 of this study</measurement>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Response</title>
        <description>Response is Complete Remission (CR) or CR with incomplete blood count recovery (CRi) according to International Working Group (IWG) consensus criteria for treatment response in Acute Myeloid Leukemia (AML) (modified): Morphological Complete Remission (CR): Normalization of the peripheral blood absolute neutrophil count &gt; 1.0x109/L, platelets &gt; than 100x109/L no residual evidence of extramedullary disease and bone marrow aspirate with ≤ 5% blasts, no blasts with Auer rods (AML only); and Morphological Complete Remission with incomplete blood count recovery (CRi): Same as CR but without normalization of the peripheral blood absolute neutrophil and platelet count.</description>
        <time_frame>Assessed after one 28-day cycle of treatment</time_frame>
        <population>Six participants in Phase II Cohort 3 were not evlauable for response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I Cohort 1 - MEK 162</title>
            <description>Phase I Starting Dose of MEK 162: 30 mg by mouth twice a day in a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Phase I Cohort 2 - MEK 162</title>
            <description>Phase I Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.</description>
          </group>
          <group group_id="O3">
            <title>Phase II Cohort 3 - MDK 162</title>
            <description>Phase II Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Response</title>
          <description>Response is Complete Remission (CR) or CR with incomplete blood count recovery (CRi) according to International Working Group (IWG) consensus criteria for treatment response in Acute Myeloid Leukemia (AML) (modified): Morphological Complete Remission (CR): Normalization of the peripheral blood absolute neutrophil count &gt; 1.0x109/L, platelets &gt; than 100x109/L no residual evidence of extramedullary disease and bone marrow aspirate with ≤ 5% blasts, no blasts with Auer rods (AML only); and Morphological Complete Remission with incomplete blood count recovery (CRi): Same as CR but without normalization of the peripheral blood absolute neutrophil and platelet count.</description>
          <population>Six participants in Phase II Cohort 3 were not evlauable for response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I Cohort 1 - MEK 162</title>
          <description>Phase I Starting Dose of MEK 162: 30 mg by mouth twice a day in a 28 day cycle.</description>
        </group>
        <group group_id="E2">
          <title>Phase I Cohort 2 - MEK 162</title>
          <description>Phase I Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.</description>
        </group>
        <group group_id="E3">
          <title>Phase II Cohort 3 - MDK 162</title>
          <description>Phase II Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and Lymphatic System Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Progressive Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Tumor Lysis Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms Benign, Malignant and Unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema Limbs</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Alkaline Phosphatase Increase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tumor Lysis Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Farhad Ravandi-Kashani MD/Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-745-0394</phone>
      <email>fravandi@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

